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Abstract: In the last decade, the tremendous improvement in the sensitivity and also affordability of
liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revolutionized its application
in pharmaceutical analysis, resulting in widespread employment of LC-MS/MS in determining
pharmaceutical compounds, including anticancer drugs in pharmaceutical research and also
industries. Currently, LC-MS/MS has been widely used to quantify small molecule oncology drugs
in various biological matrices to support preclinical and clinical pharmacokinetic studies in R&D
of oncology drugs. This mini-review article will describe the state-of-the-art LC-MS/MS and its
application in rapid quantification of small molecule anticancer drugs. In addition, efforts have also
been made in this review to address several key aspects in the development of rapid LC-MS/MS
methods, including sample preparation, chromatographic separation, and matrix effect evaluation.
Keywords: LC-MS/MS; rapid; quantification; oncology drugs
1. Introduction
Cancer has a major impact on global health as it is the second leading cause of death. According
to the World Cancer Report 2014, the number of new cancer cases is expected to rise by about 70%
over the next two decades [1]. This is due to the rapidly ageing population, unhealthy lifestyles,
and environmental pollutants, which could consist of carcinogens that can be present in the air,
water, and soil, as well as in food as additives or contaminants. Early diagnosis of cancer allows
timely treatment of the disease. Unfortunately, the early detection of cancer is still in its infancy
as the progress in developing improved early diagnostics and screening tests has been inadequate.
For instance, close to 70% of patients with lung cancer present with locally advanced or metastatic
disease at the time of diagnosis. Therefore, surgical resection, the single most consistent and successful
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option for cure, cannot be performed [2]. This thereby makes chemotherapy an important treatment
option against cancer. Anticancer drugs are characterized by a narrow therapeutic window. Hence, it is
important to understand and manage the inter-individual variability of drug exposure through
genotyping/phenotyping and therapeutic drug monitoring (TDM) of anticancer drugs in the clinical
setting. In the pharmaceutical industry, the current challenges in the development of anticancer
drugs include the significant time and cost required for the preclinical and clinical testing of the new
chemical entities (NCEs), and the low success rates. To overcome these obstacles, the pharmaceutical
industry has been increasing its effort to improve the efficiency in the processes of drug discovery
and development. This is in line with the objective of reducing the attrition rate of NCEs at later
stages of the anticancer drug development pipeline, especially in clinical trials as by that stage a large
portion of the cost of developing an oncology drug would have been incurred. According to a review
article, two major underlying reasons accounting for drug attrition were identified [3]. The first one
is due to poor efficacy, which can be overcome by developing more predictive animal models in the
preclinical phase. The second crucial factor is owing to poor pharmacokinetics (PK). To overcome the
latter hurdle, a high throughput preclinical screening PK approach should be developed and validated.
However, the success of PK analysis is highly dependent on the availability of rapid and sensitive
bioanalytical assays for quantification of drugs in biological samples. Therefore, rapid and sensitive
quantification of anticancer drugs in various biological matrices is urgently needed to discover novel
and effective chemotherapeutic agents against various cancers. Liquid chromatography-tandem
mass spectrometry (LC-MS/MS) offers superior specificity and sensitivity for compounds without
natural chromophores or fluorophores. Hence, this highly sensitive and specific platform has been
widely applied in investigating pharmacokinetic properties of novel anticancer drugs in their R&D in
preclinical studies as well as in clinical trials. The workflow of LC-MS/MS proposed for bioanalytical
method development is shown in Figure 1. The success for developing rapid and sensitive analytical
methods is dependent on appropriate sample preparation, fast chromatographic separation to achieve
symmetrical peaks, and efficient ionization.
The purpose of this review is to summarize the rapid LC-MS/MS methods for quantification
of oncology drugs or potential anticancer compounds published in PubMed and Web of Science
databases. In addition, important considerations regarding several crucial aspects in developing
rapid LC-MS/MS methods, such as sample preparation, chromatographic separation, matrix effect
evaluation, and internal standard selection will be discussed.
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2. Method of Literature Search
T e literature sea ch was conducted using the PubMed and Web of Science databases subscribed
to by the National University of Singapore. The title phrase “rapid” or “fast” AND title or abstract
phrase “LC-MS/MS” AND title or abstract phrase “cancer” were searched. The articles were then
screened for their relevance to rapid quantification of anticancer drugs by LC-MS/MS. No date
limitations were applied, and all articles retrieved were dated up to 30 May 2018. Additional relevant
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literature that was cited in the retrieved articles has also been reviewed. The scope of the review is
limited to English language articles only.
3. Results and Discussion
Based on the search method described, 72 papers have been found to be relevant to rapid
quantification of anticancer drugs using LC-MS/MS methods. All of them have been classified into
two categories based on the number of analytes. Forty-nine publications involved analyzing one drug
(n = 1) and the remaining 23 involved analyzing multiple drugs/metabolites (n ≥ 2) are summarized
in Table 1 [4–52] and Table 2 [53–75], respectively.
Currently, the unpreceded selectivity and continuously increasing sensitivity of LC-MS/MS
have made it a particularly powerful and well established analytical technique to achieve rapid
quantitation of anticancer drugs/metabolites in a very small volume of biological samples without
tedious chromatographic separation and complicated sample preparation before mass signal detection.
Some considerations in developing a LC-MS/MS for rapid quantitation of anticancer drugs will be
further elaborated as follows.
3.1. Sample Preparation
Efficient sample preparation to avoid severe signal suppression due to the matrix effect is the first
key step in achieving high sensitivity and specificity of rapid LC-MS/MS methods. Through sample
preparation, we aim to isolate the target drugs/metabolites from the various biological matrices which
contain a variety of endogenous components such as proteins, carbohydrates, salts, and lipids, etc.
In general, there are three sample preparation methods for purifying the biological samples before
injection into the MS/MS analyzer for quantitation of the target analyte(s). These sample preparation
procedures can be accomplished through solid-phase extraction (SPE), liquid-liquid extraction (LLE),
or protein precipitation (PPT). The results of all the 72 papers reviewed here suggested that PPT
accounted for half of them (50%), followed by LLE (32.4%), and then SPE (17.6%), as shown in Figure 2.
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Figure 2. Distribution of sample preparation assays. PPT: protein precipitation; LLE: liquid-liquid
extraction; SPE: solid phase extraction.
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Table 1. LC-MS/MS methods for determination of one drug.
Analyte(s) Indication Matrices Prep Solid Phase E-M Interf IS ME (%) RT (min) LLOQ Ref.
Nimorazole Radiosensitizer r-plasma PPT C18 (50 × 4.6 mm, 2.7 µm) ISO ESI(+) AN NEG 1.5 0.25 ng/mL [4]
JI-101 Multi-kinase inhibitor h-plasmah-urine SPE C18 (50 × 2.1 mm, 5 µm) ISO ESI(+) AN 98 2.0
1.57 ng/mL
0.97 ng/mL [5]
LBH589 HDAC inhibitor m-plasmam-tissue LLE
C18 (50 × 2.1 mm, 1.7 µm)
UPLC ISO ESI(+) AN NEG 2.0
2.5 ng/mL
35.7 ng/mg [6]
Vinorelbine Vinca alkaloid h-plasma LLE C18 (50 × 2.1 mm, 3 µm) ISO ESI(+) AN 95.8–106.7 2.0 0.1 ng/mL [7]
Cerivastatin Inhibitor of HMG-CoA reductase h-plasma LLE C18 (100 × 3 mm, 3.5 µm) ISO ESI(+) AN NEG 2.0 0.01 ng/mL [8]
Osimertinib Tyrosine kinase inhibitor r-plasma PPT C18 (50 × 2.1 mm, 3 µm) GRA ESI(+) AN 90.1–97.3 2.5 1 ng/mL [9]
Anastrazole Aromatase inhibitor h-plasma SPE C18 (50 × 4.6 mm, 5 µm)UPLC ISO ESI(+) AN 97.5 2.5 0.3 ng/mL [10]
SZ-685C Marine anticancer agent r-plasma LLE C18 (100 × 2.1 mm, 3 µm) ISO ESI(−) AN 94.3 2.5 5 ng/mL [11]
CLR1401 Anticancer candidate r-plasma LLE C18 (50 × 3.0 mm, 5 µm) GRA ESI(+) IL 80.0–86.0 2.8 2 ng/mL [12]
Veliparib (ABT-888) PARP-1 & 2 inhibitor h-plasma PPT C18 (100 × 2.1 mm, 3 µm) ISO ESI(+) AN UNK 3.0 5 nmol/L [13]
Docetaxel Anticancer drug h-plasma LLE C8 (50 × 2.1 mm, 5 µm) ISO ESI(+) AN UNK 3.0 5 ng/mL [14]
Aucubin Natural compound r-plasma PPT Diamonsil C18(2) ISO ESI(+) AN 90.8–91.0 3.0 10 ng/mL [15]
HCQ Inhibitor of autophagy h-blood PPT C8 (50 × 2.1 mm, 5 µm) ISO ESI(+) IL 93.0–100.6 3.0 5 ng/mL [16]
Sunitinib Tyrosine kinase inhibitor h-plasma LLE C18 (50 × 2.1 mm, 3.5 µm) ISO ESI(+) AN UNK 3.0 0.2 ng/mL [17]
DZNep Methylation inhibitor m-plasma LLE HILIC (100 × 2.1 mm, 1.7 µm)UPLC GRA ESI(+) AN 84–87 3.0 5 ng/mL [18]
SN-38 Anticancer drug h-plasma PPT C18 (50 × 2.0 mm, 4 µm) GRA ESI(+) AN UNK 3.0 0.05 ng/mL [19]
Vincristine Anticancer drug h-plasma PPT C18 (50 × 2.1 mm, 5 µm) ISO APCI(+) AN UNK 3.0 0.1 ng/mL [20]
MS-275 HDAC inhibitor h-plasma LLE C18(50 × 2.1 mm, 3.5 µm) GRA ESI(+) AN UNK 3.0 0.5 ng/mL [21]
trans-resveratrol Natural compound m-plasmam-brain LLE C18 (100 × 1 mm, 5 µm) ISO ESI(−) AN 93.8–100.6 3.0 5 ng/mL [22]
ZD6474 Tyrosine kinase inhibitor h-plasmah-fluid LLE C18 (50 × 2.1 mm, 2.6 µm) ISO ESI(+) IL 98.0 3.0
0.25 ng/mL
0.25 ng/mL [23]
Crizotinib Tyrosine kinase inhibitor r-plasma PPT Zorbax XDB C18(2.1 × 50 mm, 3.5 µm) GRA ESI(+) AN 94.3–96.2 3.5 1 ng/mL [24]
cabozantinib Tyrosine kinase inhibitor r-plasma LLE C18 (50 × 2 mm, 5 µm) ISO ESI(+) AN 105–115 3.5 0.5 ng/mL [25]
KPS-A Natural compound r-plasma PPT C18 (2.1 × 50 mm, 3.5 µm) GRA ESI(+) AN 93–96 3.5 0.5 ng/mL [26]
Clofarabine
triphosphate Metabolite of clofarabine h-PBMC PPT CN (100 × 4.6 mm, 5 µm) GRA ESI(+) AN 91–105 3.5 1.25 ng/10
7 cells [27]
Paclitaxel Antimicrotubule agent r-plasmar-tissue LLE C8 (50 × 2.1 mm, 5 µm) ISO ESI(+) IL 70.9–82.7 3.5
0.5 ng/mL
1.5 ng/g [28]
EDL-155 Anticancer agent r-plasma PPT C8 (50 × 2.1 mm, 3.5 µm) GRA ESI(+) AN 98.6 3.5 0.1 ng/mL [29]
Henatinib Kinase inhibitor h-plasmah-urine PPT C18 (50 × 2.1 mm, 2.5 µm) ISO ESI(+) AN 90.5–100.9 3.5
0.1 ng/mL
1 ng/mL [30]
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Ceritinib ALK inhibitor h-plasmah-brain PPT C18 (50 × 2.1 mm, 2.7 µm) GRA ESI(+) IL 92–109 3.6 1 ng/mL [31]
Methergine chemosensitizer for cancer h-plasma LLE C18 (100 × 2.1 mm, 2.7 µm) ISO ESI(+) AN 61–66 4.0 0.025 ng/mL [32]
Letrozole Aromatase inhibitor h-plasma SPE C18 (100 × 2.1 mm, 3.5 µm) ISO ESI(+) AN NEG 4.0 0.25 ng/mL [33]
Deacetyl
mycoepoxydiene Marine anticancer agent r-plasma PPT C18 (150 × 2.1 mm, 5 µm) ISO ESI(+) AN 95.5–97.8 4.0 5 ng/mL [34]
Sorafenib Kinase inhibitor h-plasma PPT
SymmetryShield RP8
(50 × 2.1 mm, 3.5 µm)
(0.1% FA:ACN)
ISO ESI(+) IL 98.6 4.0 5 ng/mL [35]
QBH-196 c-Met tyrosine kinase inhibitor r-plasma LLE C18 (50 × 2.1 mm, 2.6 µm) GRA ESI(+) AN 80–115 4.0 8 ng/mL [36]
Fenretinide Chemopreventive agent m-plasma PPT C18 (50 × 2.1 mm, 5 µm) GRA APCI(+) AN 100.8–108.7 4.5 0.5 ng/mL [37]
PM01183 Antineoplastic agent Animalplasma SPE C18 (30 × 2.1 mm, 3 µm) GRA ESI(+) IL 88–103 5.0 0.1 ng/mL [38]
JCC76 Antitumor agent r-plasma LLE C18 (40 × 2.0 mm, 5 µm) ISO ESI(−) AN 90.8–96.9 5.0 0.3 ng/mL [39]
Megestrol acetate Hormonal therapy h-plasma LLE C18 (50 × 2.0 mm, 3 µm) ISO ESI(+) AN 92.3–95.8 5.0 1.0 ng/mL [40]
Berbamine Natural compound r-plasma PPT C18 (150 × 2.0 mm, 5 µm) GRA ESI(+) AN 97.2–98.5 5.5 1 ng/mL [41]
Peri-plocymarin potential anticancer agent r-plasmar-tissue LLE C18 (2.1 × 150 mm, 3.0 µm) ISO ESI(+) AN 95.8–105 6.0 0.5 ng/mL [42]
ABL potential anticancer agent r-plasma PPT C18 (50 × 4.6 mm, 3.0 µm) ISO ESI(+) AN 104–108 6.0 1.6 ng/mL [43]
Cisplatin Anticancer drug r-tissue LLE C18 (50 × 2.1 mm, 1.8 µm) ISO ESI(+) AN 89–104 6.0 5 ng/mL [44]
EC-18 Anticancer agent r-plasmam-plasma PPT C18 (150 × 2 mm, 4.0 µm) GRA ESI(+) IL 77.9–89.0 7.0 50 ng/mL [45]
Z-endoxifen Anti-estrogen h-serum PPT C18 (150 × 2.1 mm, 2.6 µm) GRA ESI(+) IL NA 7.0 1 ng/mL [46]
5-azacytidine Anticancer agent h-plasma SPE C18 (250 × 2.1 mm, 4 µm) ISO ESI(+) AN 51–55 7.0 5 ng/mL [47]
RGB-286638 Protein kinase inhibitor h-plasmah-urine LLE C18 (50 × 2.1 mm, 5 µm) GRA ESI(+) IL 146–151 7.0
2 ng/mL
2 ng/mL [48]
Azurin p28 Anticancer peptide m-ser PPT C18 (100 × 2 mm, 5 µm) GRA ESI(+) AN UNK 7.5 100 ng/mL [49]
Apogossypol Bcl-2 inhibitor m-plasma PPT C18 (100 × 2 mm, 4 µm) GRA ESI(+) AN UNK 7.5 10 ng/mL [50]
Methotrexate Anticancer drug h-saliva SPE C18 (150 × 2.0 mm, 2.2 µm) GRA ESI(+) AN 96–104 8.0 1.0 ng/mL [51]
CSUOH0901 COX-2 inhibitor r-plasma PPT C18 (50 × 2.0 mm, 5 µm) GRA ESI(+) AN 90.1–94.5 8.0 0.5 ng/mL [52]
Abbreviations: Prep: sample preparation; S-Ph (M-Ph): Solid phase (Mobile phase); E-M: Elution mode; Interf: Interface; IS: Internal standard; RT: Run time;
LLOQ: Lower limit of quantitation; Ref.: Reference number; h: human; m: mouse; r: rat; d: dog; LLE: liquid-liquid extraction; SPE: solid phase extraction; PPT:
protein precipitation; ISO: isocratic elution; GRA: gradient elution; AN: analogue internal standard; IL: isotope labeled internal standard; LBH589: Panobinostat; HCQ:
Hydroxychloroquine; JCC76: Cyclohexanecarboxylic acid [3-(2,5-dimethyl-benzyloxy)-4-(methanesulfonyl-methyl-amino)-phenyl]-amide; DZNep: 3-Deazaneplanocin A; EDL-155:
1,2,3,4-tetrahydroisoquinoline; ZD6474: vandetanib; PR104: (A: alcohol; H: hydroxylamine; M: amine; G: O-glucuronide); CA4P: combretastatin A4 phosphate; CA4: combretastatin
A4; CA4G: combretastatin A4 glucuronide; ABL:1-O-acetylbritannilactone; KPS-A: kalopanaxsaponin A; QBH-196: N1-(3-fluoro-4-{6-methoxy-7-[3-(4-methylpiperidin-1-yl) propoxy]
quinolin-4-yloxy}phenyl)-N4-(2,4-difulurobenzylidene) semicarbazided; NA: not available; NEG: negligible matrix effect; UNK: unknown; ME: matrix effect; UPLC: Ultra-Performance
Liquid Chromatography.
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Table 2. LC-MS/MS methods for determination of two or more drugs/metabolites.
Analyte(s) Indication Matrices Prep S-Ph E-Mode Interf IS ME (%) RT (min) LLOQ Ref.
Belinostat
Panobinostat
Rocilinostat
Vorinostat
HDAC inhibitor r-plasma PPT C18 (50 × 4.6 mm, 5 µm) ISO ESI(+) AN
No
significant
ME
2.5
2.9 ng/mL
2.9 ng/mL
1.0 ng/mL
1.0 ng/mL
[53]
CT-707
CT-707M1
CT-707M2
Tyrosine kinase
selective inhibitor h-plasma SPE
C18 (2.1 × 50 mm, 1.7 µm)
UPLC GRA ESI(+) IL 86.9–102 3.0
2 ng/mL
1 ng/mL
1 mg/mL
[54]
Gefitinib
O-DMG EGFR inhibitor h-plasma PPT C18 (150 × 2.1 mm, 5 µm) ISO ESI(+) AN
93.0–103.3;
41.6–50.2 3.0 5 nmol/L [55]
Sunitinib
Gefitinib
Norimatinib (met)
Imatinib
Dasatinib
Erlotinib
Axitinib
Nilotinib
Lapatinib
Sorafenib
Nine tyrosine kinase inhibitors and one
metabolite of Imatinib h-pls SPE
C18 (50 × 2.1 mm, 1.7 µm)
UPLC GRA ESI(+) IL
96.6
104.5
85.5
85.0
84.5
81.6
113.1
101.8
91.2
107.7
4.0
10 ng/mL
0.1 ng/mL
10 mg/mL
10 ng/mL
0.1 ng/mL
10 mg/mL
0.1 ng/mL
10 ng/mL
10 mg/mL
0.1 mg/mL
[56]
MTX
7-OH-MTX Anticancer drug
m-plasma
m-brain PPT C18 (50 × 2.0 mm, 5 µm) ISO ESI(+) IL 88.2–108.8 4.0
3.7 ng/mL
7.4 ng/mL [57]
17 tyrosine kinase
inhibitors EGFR tyrosine kinase inhibitors h-plasma SPE
C18 (5 × 2.1 mm, 1.6 µm)
UPLC GRA ESI(+) IL 83.4–116.40 5.0 0.1 ng/mL [58]
Doxorubicin
L-DOX Anticancer antibiotic h-plasma SPE C18 (50 × 2.1 mm, 5.0 µm) GRA ESI(+)
AN
IL 95.7–98.9 5.0
3.13 ng/mL
0.15 µg/mL [59]
Vemurafenib,
Dabrafenib
Cobimetinib,
Trametinib
Binimetinib
2 BRAF inhibitors
3 MEK inhibitors h-plasma SPE
C18 (100 × 2.1 mm, 5.0 µm)
UPLC GRA ESI(+) IL 80.6–115.4 5.0
0.4 ng/mL
1.0 ng/mL
0.5 ng/mL
0.5 ng/mL
0.75 ng/mL
[60]
Thalidomide
Lenalidomide
Cyclophosphamide
Bortezomib
Dexamethasone
Adriamycin
Anticancer drug h-serum SPE C18 (50 × 2.1 mm, 2.5 µm) GRA ESI(+) AN
89–100
60–64
113–124
103–126
90–92
143–163
5.0
4 ng/mL
2 ng/mL
2 ng/mL
2 ng/mL
2 ng/mL
2 ng/mL
[61]
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MG
PGG Natural compounds r-blood LLE
C18 (50 × 2.1 mm, 5 µm)
UPLC GRA ESI(+) AN
76–87
80–104 5.0
19.5 nmol/L
39 nmol/L [62]
Allitinib
M6
M10
Irreversible inhibitor of the EGFR 1/2 h-plasma PPT C18 (50 × 4.6 mm, 1.8 µm) GRA ESI(+) AN 98.7–105.0 5.0
0.3 ng/mL
0.03 ng/mL
0.075 ng/mL
[63]
Gefitinib
Erlotinib
Afatinib
EGFR tyrosine kinase inhibitors h-plasma LLE C18 (50 × 2.1 mm, 3.5 µm)UPLC ISO ESI(+) AN UNK 5.0
0.01 nmol/L
0.01 nmol/L
0.05 nmol/L
[64]
CP
4OHCP Anticancer drug h-plasma PPT C18 (150 × 2.1 mm, 5 µm) GRA ESI(+)
IL
AN UNK 6.0
0.2 µg/mL
0.05 µg/mL [65]
Clofarabine
Cytarabine Anticancer drug h-plasma PPT C18 (150 × 2.0 mm, 4 µm) GRA ESI(+) AN None 6.0
8 ng/mL
20 ng/mL [66]
Gefitinib
M523595
M537194
M387783
M608236
EGFR tyrosine kinase inhibitor & its metabolites m-plasma PPT C18 (50 × 2.1 mm, 1.8 m) GRA ESI(+) AN 86–112 6.0
1 ng/mL
1 ng/mL
1 ng/mL
1 ng/mL
1 ng/mL
0.5 ng/mL
[67]
Exemestane
17β-2H-EXE
17β-2H-EXE-Glu
Steroidal aromatase inhibitor h-plasma PPT C18 (100 × 2.1 mm, 5 µm) GRA ESI(+) AN
62.2
54.2
33.8
6.0
0.4 ng/mL
0.2 ng/mL
0.2 ng/mL
[68]
CPT-11
SN-38
SN-38G
APC
NPC
Topoisomerase I inhibitor h-plasma PPT C18 (50 × 2.0 mm, 2.6 µm) GRA ESI(+) AN 91.0 6.0
0.5 ng/mL
0.2 ng/mL
0.5 ng/mL
0.5 ng/mL
0.2 ng/mL
[69]
Sinotecan
7-HEC Anticancer agent h-blood PPT C8 (150 × 4.6 mm, 5 µm) GRA ESI(+) AN 104–114 6.0
1 ng/mL
0.5 ng/mL [70]
Letrozole
Carbinol
carbinol glucuronide
Aromatase inhibitor and its metabolites h-pls SPE C18 (50 × 4.6 mm, 1.8 µm)UPLC GRA ESI(+) IL
30–31
90–100
6.0
20 nmol/L
0.2 nmol/L
2 nmol/L
[71]
PR104
PR-104A
PR-104G
PR-104H
PR-104M
Hypoxia-activated prodrug h-plasma PPT C18 (50 × 2.1 mm, 1.8 µm)UPLC GRA ESI(+) IL 87.4–112.6 6.0
0.1 µmol/L
0.05 µmol/L
0.05 µmol/L
0.025 µmol/L
0.01 µmol/L
[72]
CA4P
CA4
CA4-Glu
Antitumor vascular disrupting agent d-plasma PPT C18 (150 × 3.0 mm, 5 µm) GRA
ESI(+)
ESI(+)
ESI(−)
AN NEG 6.0 5 ng/mL [73]
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Table 2. Cont.
Paclitaxel
Docetaxel
Vinblastine
Vinorelbine
Regulators of microtubule formation h-plasma LLE C18 (100 × 2.1 mm, 3.5 µm) ISO ESI(+) AN 86.7–102.5 6.0
25 ng/mL
10 ng/mL
10 ng/mL
10 ng/mL
[74]
17AAG
17AG HSP90 inhibitor h-plasma PPT C18 (50 × 2.1 mm, 5 µm) GRA ESI(+) AN UNK 7.0
0.5 ng/mL
0.5 ng/mL [75]
Abbreviations: Prep: sample preparation; S-Ph (M-Ph): Solid phase (Mobile phase); E-mode: Elution mode; Interf: Interface; IS: Internal standard; RT: Run time; LLOQ: Lower limit of
quantitation; Ref.: Reference number; h: human; m: mouse; r: rat; d: dog; LLE: liquid-liquid extraction; SPE: solid phase extraction; PPT: protein precipitation; ISO: isocratic elution; GRA:
gradient elution; AN: analogue internal standard; IL: isotope labeled internal standard; CP: Cyclophosphamide; 4OHCP: 4-hydroxycyclophosphamide; O-DMG:O-desmethyl gefitinib; MTX:
Methotrexate; L-DOX: Liposomal doxorubicin; LBH589: Panobinostat; MG: methyl gallate; PGG: pentagalloyl glucopyranose; 17β-2H-EXE: 17β-hydroxyexemestane; 17β-2H-EXE-Glu:
17β-hydroxyexemestane-17-O-β-D-glucuronide A; 7-HEC: 7-hydroxyethyl-camptothecin; PR104: (A: alcohol; H: hydroxylamine; M: amine; G: O-glucuronide); CA4P: combretastatin A4
phosphate; CA4: combretastatin A4; CA4G: combretastatin A4 glucuronide; 17AAG: 17-(allylamino)-17-demethoxygeldanamycin; 17AG: 17-amino-17-demethoxygeldanamycin; NEG:
negligible matrix effect; SIG: significant matrix effect; UNK: unknown.
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SPE makes use of the affinity of solutes dissolved or suspended in a liquid (known as the mobile
phase) to a solid matrix when the sample solution or suspension is passed through a cartridge packed
with solid matrix, known as the stationary phase. During the process, the undesired endogenous
components as well as the exogenous interfering compounds generated during the sample preparation
process (e.g., plasticizers released from plastic tubes) have less affinity for the stationary phase.
They readily pass through the cartridge leaving the analytes behind in the cartridge. After that,
the analytes can be washed out from the cartridge using a different solvent in which the analytes have
higher solubility. This process can remove interfering compounds efficiently through optimizing the
types of cartridges and solvents used. In addition, it also allows for the enrichment of analytes when
very low levels of drugs/metabolites are available to be quantified (e.g., in the situation involving
microdosing of anticancer drugs in clinical trials). However, SPE is a labor-intensive process due to its
complex procedure including column conditioning, sample loading, washing, and eluting, followed
by evaporation of the eluent. This might account for only 18.1% of 72 papers in which the SPE was
adopted. In addition, SPE cartridges are more expensive than the small volume of solvent used
in LLE and PPT. Furthermore, PPT and LLE are more commonly used in quantification of single
drugs/compounds. Only 12.2% of papers cited in Table 1 used SPE for sample preparation, but the
usage of LLE is 40.8%, which is 2-fold higher than that of SPE. However, SPE was more popularly
used in simultaneous quantification of multiple analytes/metabolites than LLE. Based on Table 2,
the percentage of SPE was greatly increased to 30.4% with a substantial decline of LLE usage to 13.0%.
Nevertheless, application of SPE cartridges is limited when the drug of interest and its metabolites
have very different solubility.
LLE is commonly used in the chemistry laboratory and the pharmaceutical industry to separate
compounds based on their relative solubility in two different immiscible liquids, which are usually
aqueous or biofluid samples, and an organic solvent such as hexane or ethers. It encompasses an
extraction of a substance from one liquid into another liquid phase. LLE is especially suited to lipophilic
compounds since the analytes transfer readily from the usually aqueous matrix to an organic phase.
This procedure is followed by evaporation of the organic phase with OFN (oxygen-free nitrogen).
Comparatively, LLE is much simpler and relatively inexpensive compared to SPE. However, it is
not suitable for hydrophilic drugs/metabolites, unless derivatization is done (which is commonly
used for GC-MS). Hence, LLE is usually used for determination of a single analyte but not suitable
for simultaneous quantification of multiple drugs which have significantly different lipophilicity,
resulting in large and different recoveries among the analytes.
PPT is the simplest method of sample pre-treatment as it involves only the addition of a
precipitating solvent, subsequent vortex, and centrifugation. The more frequently used solvents for
PPT include acetonitrile and methanol. The resulting supernatant is then injected into the LC-MS/MS
system for analysis. The advantage of PPT is simple, rapid, and inexpensive. In addition, it is suitable
for both lipophilic and hydrophilic analytes. This is a very unique feature as compared to SPE and
LLE that cannot extract hydrophilic compounds. This unique property of PPT is very important
for quantitative analysis of the relatively hydrophilic drugs or for simultaneous determination of
lipophilic drugs with both their lipophilic and hydrophilic metabolites (e.g., exemestane and its
phase I and phase II metabolites, 17β-2H-exemestane and 17β-2H-exemestane-O-glucuronide) [68].
PPT, however, does not always produce very clean extracts, as many matrix constituents can
be extracted simultaneously with the analyte. That can interfere with the MS/MS detection.
The interference can be particularly serious when the volume of the biological sample is large (>50 µL).
In summary, there was a significant difference in application of these three methods. The number
of studies using PPT alone was equivalent to the combined number of studies using LLE and SPE.
In addition, the percentage of LLE at 31.9% was much greater than that of SPE at 18.1%. Based on
Table 2, SPE played an important role for simultaneous quantification of multiple drugs/compounds.
Only PPT can be used as the sample preparation procedure for the simultaneous quantitation of
parent drugs and their hydrophilic metabolites. Taken together, PPT is the most widely used method
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for preparation of biological samples. The major reason is that most of the metabolites are much
more hydrophilic than their parent drugs, particularly for Phase II metabolites which are not able
to be extracted with LLE and SPE. However, PPT can extract both a parent drug and its metabolites
at an equally high recovery. Therefore, PPT becomes the first choice for sample preparation due
to the extremely high selectivity of the MS/MS analyzer and its increasingly improved sensitivity,
making quantification of analytes in a small micro volume of biological samples (≤10 µL) possible.
3.2. Chromatographic Separation
Chromatography is undoubtedly the most important analytical method for identification and
quantitation of a drug and its metabolites since 1952, when Archer J.P. Martin and Richard L.M.
Synge were jointly awarded the Nobel Prize in Chemistry for their proposed concept of partition
chromatography. Based on the concept, various chromatographic techniques and columns have been
developed to separate chemicals with only slight differences in partition coefficients between the mobile
and stationary phases. Since the second half of the 20th century, liquid chromatography has been
widely used in analysis in the pharmaceutical industry for bioanalysis of drugs in preclinical studies
and clinical trials. A lot of analytical methods have been published on the determination of various
drugs with liquid chromatography coupled with a UV detector. However, this analytical process used
for quantification of analytes in biological samples is quite tedious and time consuming due to the poor
selectivity of UV detection—a widely used analytical approach for pharmaceutical analysis in the last
century. For analysis using liquid chromatography with UV detection, sample preparation is usually
very challenging for analytical scientists as endogenous compounds and co-administered drugs have
to be removed via sample preparation as much as possible to minimize the background interference
in the analysis. The chromatographic run time is usually long, ranging from 30 to 60 min. This is
because the target drugs/metabolites have to be chromatographically separated from both endogenous
and exogenous interfering compounds prior to detection and measurement. In the mid last century,
a revolutionary change in pharmaceutical analysis was made when the LC-MS/MS was invented.
In contrast to most LC-UV analytical methods, LC-MS/MS is able to discern the analyte(s) from the
matrix components with the presence of other endogenous substances and spiked internal standards,
even if they are co-eluted due to the superior selectivity of MS/MS. However, the potential problem
of harmful ion suppression or enhancement from the co-eluting peaks still has to be overcome in the
process of developing and validating the LC-MS/MS methods for rapid determination of anticancer
drugs/metabolites. This will be further elaborated in the later part of this review.
The extremely high selectivity and continuously increasing sensitivity of MS/MS lays the
foundation for achieving a rapid quantification of analytes in various biological matrices. The run
time (RT)—the total time necessary for completing a chromatographic separation—reported in the
72 papers, has been summarized in Tables 1 and 2. Their distribution was shown in Figures 3 and 4,
respectively. Based on Figure 3, the two top percentages of the fastest run times are 36% and 28%
(both are shaded) for RT 1.5→ 3.0 min and 3.1→ 4.0, respectively, for the determination of 1 analyte.
The combined percentage with these 2 RTs is equal to 64%. Hence, it is reasonable to define a run time
of ≤4 min as rapid quantification of one drug in biological matrices. On the other hand, a run time
of ≤6 min could be defined as rapid quantification of ≥2 analytes based on Figure 4 in which two
top percentages of the fastest run times are 39% and 38% (both are shaded) for RT 4.1→ 5.0 min and
5.1→ 6.0, respectively. This is because as many as 92% of the papers listed in Table 2 reported a RT
of ≤6 min for the chromatographic separation of analytes or above. Taken together, the run time to
achieve rapid analysis for 1 drug and ≥2 drugs/metabolites are 4 and 6 min, respectively.
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is only used in 6.1% of all studies for analyzing one analyte, as shown in Table 1. For instance,
Bouchet et al. reported a well-validated UPLC-MS/MS method for simultaneous determination of
nine tyrosine kinase inhibitors within 4 min of run time only [56]. Similarly, Merienne et al. achieved
high throughput routine determination of 17 tyrosine kinase inhibitors by another UPLC-MS/MS
method [58]. In addition, UPLC separation with gradient mode also improves the peak shapes of the
later-eluting compounds and gives chromatographic bands that are more evenly spaced [77].
Contrary to HPLC-UV methods, a baseline chromatographic separation is not needed in
LC-MS/MS analysis to elute the target analytes from other interfering compounds during method
development, especially for determination of one drug while its metabolites present different mass
transitions. However, when a drug and its metabolites are determined simultaneously, the separation
between a parent drug and its metabolites is usually necessary as the metabolites, particularly its
phase II conjugated metabolites, may have similar fragmentation profiles as the parent drug, leading to
inaccurate measurement of the analyte [78].
With reference to the papers listed in Table 2, some authors only indicated the stationary phase and
mobile phase conditions used without discussion in detail of the optimization of the chromatographic
separation, while the rest reported a multi-factorial optimization on LC column selection (C8 or C18),
mobile phase components, and ratios, as well as the flow rates of the mobile phase. Generally, all these
optimizations were empirical and not much theoretical explanation was given. Nevertheless, a research
group in the US proposed a theory-guided efficient strategy to maximize the speed and resolution
in rapid gradient LC-MS/MS analysis [79]. They systematically studied the effect of gradient time,
initial and final eluent strength (% organic), and flow rate on the separation resolution and peak capacity
in a gradient elution of a mixture of five structurally-related compounds. It was also demonstrated
experimentally that increasing flow rate improves both resolution and peak capacity in a rapid gradient
method. The results can be well explained mathematically using the linear-solvent-strength (LSS)
gradient theory. This further supports our finding that UPLC-coupled gradient elution is an efficient
approach for simultaneous quantification of multiple analytes in a short run time (≤6 min). In regard
to internal standards, as many as 74.3 of the internal standards from 72 papers are structural analogues
even though stable isotopically labelled (SIL) analogues of the analytes are preferred in achieving
better quantitative results. The main reasons are (1) not commercially available or (2) too expensive.
3.3. Matrix Effects
Although MS/MS has been demonstrated to possess superior selectivity and sensitivity, the signal
is often affected significantly by the biological matrix residues. Ion suppression or enhancement
remains an inherent problem in LC-MS/MS method development and could be the result of
interference of endogenous substances from the biological matrices (e.g., human plasma) or exogenous
substances during sample preparation (e.g., polymers from polypropylenetubes) [80]. The alteration
of ionization efficiency by the presence of co-eluting substances is called “matrix effects”. These effects
are not detectable in the chromatogram but have deleterious impacts on the method’s accuracy and
sensitivity. Hence, an assessment of matrix effects is needed according to the European Medicine
Agency (EMA) and USA Food and Drug Administration (FDA) guidelines so as to ensure that precision,
selectivity, and sensitivity of LC-MS/MS analyses are not compromised [81]. A series of experiments
were conducted to explore the mechanism of matrix effects and the authors concluded that the possible
reason was due to the result of competition between non-volatile matrix components and analyte ions
for access to the droplet surface for transfer to the gas phase [82]. Therefore, application of suitable
methods for the evaluation of matrix effects plays an important role in developing and validating
a sensitive and robust analytical method for the determination of anticancer drugs/metabolites in
biological matrices.
Generally, there are two common methods to assess matrix effects. One is the post-extraction
addition method, while the other is the post-column infusion method. In 2003, Matuszewski et al.
published a research paper discussing the strategies for the assessment of the matrix effect in
Pharmaceutics 2018, 10, 221 13 of 20
quantitative bioanalytical methods based on LC-MS/MS [80]. The matrix effect during validation
of analytical methods in biological fluids may be best examined by comparing the MS/MS response
(peak areas or peak heights) of an analyte at any given concentration spiked post-extraction into a
biological fluid extract (B), to the MS/MS response (A) of the same analyte present in the “neat” mobile
phase. The equation of matrix effect (%) can be expressed as follows:
ME (%) = B/A × 100. (1)
A value of 100% indicates that the responses in the “neat” mobile phase and the plasma extracts
were the same and no absolute matrix effect was observed. A value of >100% indicates an ionization
enhancement and a value of <100% indicates an ionization suppression. The post-extraction addition
technique is a quantitative but static approach that only provides information about matrix effects at
the point of elution of the analyte. A more dynamic technique for determining matrix effects is the
post-column infusion method [82]. The post-column infusion system is schematically represented
in Figure 5. An infusion pump was used to deliver a constant flow of analyte at a concentration in
the range of quantitation into the chromatographic eluent at a point after the column and before the
mass spectrometer ionization source [83]. A sample of extract (without added analyte) was injected
under the desired chromatographic conditions and the response from the infused analyte recorded.
The post-infusion technique enables the influence of the matrix on analyte response to be investigated
over the entire chromatographic run. Nevertheless, the post-infusion approach is a qualitative or
semi-quantitative method. It can be used to evaluate the influence of different sample extraction
methods, chromatographic conditions such as mobile phase components, and analytical columns on
matrix effects.
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Due to the critical influence of matrix effects on mass analyzers, matrix effects have to be evaluated
systematically during the development of well-validated and rapid LC-MS/MS methods. Among
the 72 papers of rapid analytical LC-MS/MS methods for determination of anticancer drugs and
their metabolites in Tables 1 and 2, 11 papers did not mention matrix effects. Two of them were
published in 2003 when the impact of matrix effects on the LC-MS/MS methods had not been fully
recognized by analytical scientists. Nevertheless, the majority of the studies incorporated in our
review (61 out of 72, 84.7%) have reported matrix effects of the analytes in various biological samples
during method development and validation. In addition, the matrix effects in all of these 61 papers
were evaluated using the post-extraction addition approach. The reasonable explanation is that the
post-extraction addition technique is a quantitative approach for the evaluation of matrix effects on the
analytes. Based on the quantitative analysis of matrix effects, effective solutions to overcome potential
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matrix effects or at least minimize the influence of matrix effects on sensitivity and accuracy of the
LC-MS/MS methods are needed during method development.
The matrix effect is a common phenomenon in the quantitation of drugs and metabolites in
biological matrices using LC-MS/MS. Since the matrix effect could be potentially caused by the
influence of co-eluting non-volatile matrix components on the ionization efficiency of the analytes,
it can be minimized, avoided, or compensated mainly through optimization of sample preparation,
chromatographic separation, and suitable internal standard, respectively. In theory, SPE is an ideal
sample preparation assay in which matrix effects can be eliminated efficiently because the analytes can
be efficiently isolated from the matrix via suitable SPE columns and elution solutions. However, it is
a very tedious and time-consuming process. Comparatively, LLE is a simpler and faster procedure
for the preparation of biological samples but the purified samples may still contain some lipophilic
endogenous compounds which could potentially affect the quantification of analytes. In such a case,
chromatographic separation can be optimized to minimize the resulting matrix effects due to inherent
limitation of LLE. As a widely used bio-sample preparation assay, PPT is the most convenient approach,
but the purified samples may also be much dirtier than the samples extracted by the SPE or LLE
techniques. However, an important fact to note is that increasingly improved sensitivity of LC-MS/MS
provides us a good chance to use a minute volume of biological samples, e.g., 5 µL of plasma or
serum for analysis. In this scenario, the residue of impurities derived from PPT is negligible in most
cases. This is the reason why PPT was adopted as the sample preparation for rapid determination of
anticancer drugs/metabolites using a LC-MS/MS platform in the majority of the 72 papers reviewed.
4. Conclusions and Perspectives
Rapid liquid chromatography-tandem mass spectrometry plays an important role in both
preclinical development and clinical trials. Based on the papers published in English, the assay
run times of rapid LC-MS/MS methods for a single analyte and multiple analytes were identified
as 4 and 6 min, respectively. With the development of UPLC systems and the availability of
more isotopically-labelled internal standards, assay run times for rapid analysis of anticancer
drugs/metabolites could be further reduced in order to accelerate drug development.
In the preparation of biological samples, PPT is widely applied as it is the simplest
sample preparation approach and can be used to quantify both hydrophilic and lipophilic
compounds simultaneously, thereby making it the most popular method compared to SPE and
LLE. Structural analogues are mostly used as internal standards, given the consideration of costs
and availability. In the future, great effort should be made to establish the principles in selection of
appropriate internal standards, which are chosen mainly based on a trial and error approach.
Currently, LC-MS/MS has been widely used to investigate pharmacokinetics of oncology drugs
to support early phase clinical trials and determine potential drug–drug interactions. The advantage
in using LC-MS/MS is its super sensitivity and specificity, which makes it a powerful tool for clinical
therapeutic monitoring of oncology drugs.
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